The results, which validate the safety and a first proof of efficacy for Valedia®, will be presented during a poster session on 11 June from 12 pm to 1 pm (Hall B).
TWO PARTNERSHIP AGREEMENTS TO ASSESS THE EFFECTS OF TOTUM-63, THE ACTIVE INGREDIENT OF VALEDIA®, ON INTESTINAL MICROBIOTAApril 12th 2017
VALBIOTIS, a company that specializes in developing innovative nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients, has announced today the signing of two partnership agreements, one with Biofortis (Merieux NutriSciences), and the other with the Université Catholique de Louvain (Belgium) and Prof. Patrice D. Cani1 (PhD) as part of a program aimed at evaluating the efficacy of TOTUM-63, the active ingredient of Valedia®, on intestinal microbiota.
VALBIOTIS AT THE 77TH SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATIONMarch 30th 2017
VALBIOTIS will present an overview of the results of its Phase I/II clinical study on Totum-63, the active ingredient of Valedia®, at the 77th scientific session of the American Diabetes Association (ADA).
VALBIOTIS SUCCESSFULLY COMPLETES SECOND FINANCING ROUND OF 2.2 MILLION EUROSMay 31st 2016
After having raised 1.8 million euros thanks to a first financing round in November 2014, the young La Rochelle-based company has once again proven its ability to innovate, keep its objectives and pursue its business plan.